Amarin Corp

AMRN

Market cap $319M

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.

Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.

AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.

Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized.

AMRN, AMTB and AAWH have been added to the Zacks Rank #5 (Strong Sell) List on January 28th, 2026.

The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny labels" for their products that remove specific, patented uses of a brand-name medication.

AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin's VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.